[{"orgOrder":0,"company":"Phare Bio","sponsor":"ARPA-H","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Antibiotic-based Thearpy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Phare Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Phare Bio \/ ARPA-H","highestDevelopmentStatusID":"3","companyTruncated":"Phare Bio \/ ARPA-H"}]

Find Clinical Drug Pipeline Developments & Deals by Phare Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : The fund aims to support the Phare's drug discovery engine to produce novel antibiotics against specific bacterial disease indications such as drug-resistant urinary tract infections & pneumonia.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 26, 2024

                          Lead Product(s) : Antibiotic-based Thearpy

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Sponsor : ARPA-H

                          Deal Size : $27.0 million

                          Deal Type : Funding

                          blank